• Explore /
  • Poster
  • / Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy.

Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy.

Abstract Video & Slides Poster

Authors

null

Vadim S Koshkin

Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA

Vadim S Koshkin , Divya Natesan , Li Zhang , David Yoonsuk Oh , Sima P. Porten , Maxwell Meng , Raj Pruthi , Rahul Raj Aggarwal , Eric Jay Small , Lawrence Fong , Terence W. Friedlander

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02451423

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 442)

DOI

10.1200/JCO.2021.39.6_suppl.442

Abstract #

442

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Vadim S Koshkin

First Author: Hongsik Kim

First Author: Richard Cathomas

First Author: Ali Raza Khaki